Market Research Logo

Hospitals & Clinics Market Research Reports & Industry Analysis


Hospitals & Clinics Industry Research & Market Reports

  • Spain Pharmaceuticals & Healthcare Q4 2018

    ... of the generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for ... Read More

  • Canada Pharmaceuticals & Healthcare Q4 2018

    ... environment maintains Canada's attractiveness for drugmakers,including opportunities to establish manufacturing facilities. However, drugmakers will be challenged by the increasing use ofaggressive pricing policies, with historically high generics prices increasingly becoming a target for cost-containment measures. Read More

  • Tanzania Pharmaceuticals & Healthcare Q4 2018

    ... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More

  • Philippines Pharmaceuticals & Healthcare Q4 2018

    ... prominent theme within the Philippines pharmaceutical market, repressing drugmakersales growth. With the expansion of universal health coverage, these pressures will increase, offsetting the positive impact ofincreased access to services and a reduction in out-of-pocket payments. Read More

  • Indonesia Pharmaceuticals & Healthcare Q4 2018

    ... health insurance scheme (JKN), further expansion will be hampered by deficit,investment shortages and uneven levels of healthcare access across the country. Additionally, for the pharmaceutical industry, theJKN's positive impact on growth is likely to wane ... Read More

  • Kyrgyzstan Pharmaceuticals & Healthcare Q4 2018

    ... Kyrgyzstan's small and highly ruralised population will continue to restrict opportunities for multinational pharmaceuticalfirms. Key barriers for access to modern medicines include a lack of spending power and challenges in supply and distributionacross the country. Read More

  • Puerto Rico Pharmaceuticals & Healthcare Q4 2018

    ... targeting drug spending rise and the US administration maintainsa stringent stance towards securing federal healthcare funds for Puerto Rico. Economic challenges and outward migration of labourwill further raise risks to the island's attractiveness to manufacturers, ... Read More

  • Colombia Pharmaceuticals & Healthcare Q4 2018

    ... Colombia. However, despite price control measures and a weak intellectual property environment, healthcarereforms and the rising burden of chronic diseases will facilitate the rising demand for medicines – boosting the consumption ofmedicines in volume terms. Read More

  • Morocco Pharmaceuticals & Healthcare Q4 2018

    ... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More

  • Iran Pharmaceuticals & Healthcare Q4 2018

    ... and has triggered intense negotiations surrounding theIslamic Republic's future ability to integrate into the global economy. Although the supply of medical equipment and devices willsteadily decline, Iran's healthily domestic drug production capabilities and limited exposure ... Read More

  • Saudi Arabia Pharmaceuticals & Healthcare Q4 2018

    ... 2030’ encouraging the expansion of manufacturingagreements in the country. While regulatory risks remain prevalent, and recent disputes with European players highlightchallenges of doing business in the country, positive market drivers will ensure robust long-term opportunities ... Read More

  • Laos Pharmaceuticals & Healthcare Q4 2018

    ... improving the population’s access to healthcare, the still underdevelopedhealth system will limit drugmaker opportunities. While the rising burden of communicable diseases and the gradual rolling-out ofuniversal healthcare will present improved commercial opportunities for drugmakers over ... Read More

  • Peru Pharmaceuticals & Healthcare Q4 2018

    ... to medicine, butwith limited resources available to the government, cost containment measures will pose challenges to innovative drugmakers.However, the improved but hostile political environment, following the resignation of the formal president poses upside risks toinvestment. Read More

  • Estonia Pharmaceuticals & Healthcare Q4 2018

    ... patients with high drug costs. Over the long-term,patented medicine sales will be supported by an ageing demographic and the high prevalence of cardiovascular disease andcancers. However, multinational drugmakers’ interest in the market will remain limited ... Read More

  • Ethiopia Pharmaceuticals & Healthcare Q4 2018

    ... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More

  • Russia Pharmaceuticals & Healthcare Q4 2018

    ... policy continuity will lead toincreased investment in localised drug production in the market, although this will remain heavily weighted towards the genericmedicines sector given the continued regulatory issues and market access barriers for innovative drugmakers. Read More

  • North America Population Health Management Market Forecast 2018-2026

    ... the healthcare industry has positively influenced the population health management market in this region. MARKET INSIGHTS The United States accounts for 40% of the world’s healthcare expenditure. Also, the implementation of affordable care act in ... Read More

  • Europe Population Health Management Market Forecast 2018-2026

    ... enables patient risk control and cost management is one of the key application in this market. MARKET INSIGHTS The market is segmented according to the applications, end-users, mode of delivery and components. At present, the ... Read More

  • Asia Pacific Population Health Management Market Forecast 2018-2026

    ... The market is predicted to showcase the highest growth for the forecast period as compared to other regional markets. The market segments include components, end-users, applications, and mode of delivery. China, India, and Japan are ... Read More

  • Global Population Health Management Market Forecast 2018-2026

    ... the market growth are increasing healthcare expenditure, government spending, rising need for cost-effective healthcare for the growing geriatric population, the recent application of artificial intelligence technique in PHM and the continued support for PHM in ... Read More

  • Norway Pharmaceuticals & Healthcare Q4 2018

    ... an improved fiscal outlookover the coming quarters, while the government will continue to support health industries development. That said, Norway’s smallpharmaceutical market size relative to regional peers, combined with cost control measures, will keep a ... Read More

  • Angola Pharmaceuticals & Healthcare Q4 2018

    ... training doctors and nurses, weakening the pharmaceutical andhealthcare sectors. Angola’s new President, João Lourenço, has pledged to combat corruption, attract foreign investment andimprove healthcare services. However, we continue to view Angola as one of the ... Read More

  • Argentina Pharmaceuticals & Healthcare Q4 2018

    ... increasing burden of chronic diseases will boost demand for medicines.Combined with increasing healthcare expenditure and the successful implementation of healthcare reforms, will bolster country'sattractiveness in the long term. However, in the short term, weak intellectual ... Read More

  • Ireland Pharmaceuticals & Healthcare Q4 2018

    ... the sector, will continue to limit the country’sattractiveness to drugmakers. We highlight upside risks to our forecasts dependent upon the success of the implementation of thehealth system reform. More broadly, the significant dependence of the ... Read More

  • Lithuania Pharmaceuticals & Healthcare Q4 2018

    ... the reduction in value-added tax on reimbursed medicines.Additionally, drug reimbursement is relatively limited and co-payments on reimbursed products are sizeable, which means privateexpenditure on drugs is considerable and thus vulnerable to wider economic downturns. Still, ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog